Carl Zeiss Meditec Invests in MicroOptx, a Developer of Surgical Treatments for Glaucoma


DUBLIN, Calif.—Carl Zeiss Meditec announced last Thursday that it has become a shareholder of MicroOptx Inc., headquartered in Minneapolis, Minn. MicroOptx is a privately held company focused on new, minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical technology is designed to provide effective reduction of intraocular pressure (IOP) with a simple surgical procedure, Zeiss said in a statement. The MicroOptx website described the procedure as “a platform technology to shunt aqueous humor from the anterior chamber to the surface of the eye.”

Zeiss did not specify the extent of its investment in MicroOptx. Zeiss said it supports “breakthrough surgical treatments for glaucoma and believes MicroOptx’s MIGS solution will complement our leading portfolio of equipment and consumables in ophthalmic surgery.”

James V. Mazzo, global president ophthalmic devices at Carl Zeiss Meditec, commented, “The investment in MicroOptx will give Zeiss an early position in this new technology designed to increase MIGS adoption for treating glaucoma.”